Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Horizon Discovery and Hisun Pharmaceuticals Partner on Bioproduction Cell Line

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Precisely engineered CHO cell line will enable faster, more efficient development in production of therapeutic antibodies.

Horizon Discovery announced it has entered into an agreement with Hisun Pharmaceuticals (Hisun) to optimize Horizon’s newly engineered CHO bioproduction cell line for commercial use. Hisun will be using Horizon’s glutamine synthetase (GS) double knock-out cell line for use in therapeutic antibody manufacturing. Financial terms of the agreement were not disclosed.

Horizon has engineered the CHO cell line using its GENESIS™ gene editing technology, providing the most precisely engineered GS double knock-out available. The precision afforded by GENESIS results in an optimal final genotype, with complete control over the desired genomic alterations and with no unwanted off-target effects.

GS is a critical enzyme in the metabolism of the amino acid L-glutamine which is often used as a selection marker in the production of recombinant proteins. GS-negative CHO cell lines have proven to be a valuable resource for stringent selection of high producing lines and accelerating the development of cell lines within the Bioproduction industry, offering significant advantages over traditional methods that use an expensive and toxic chemical inhibitor of GS.

Haibin Wang, Senior Vice President, Hisun Pharmaceuticals, said: “Hisun’s competitive edge comes from our focus on pioneering technology and quality product. Horizon’s gene engineering technology is unique in the level of precision it can deliver, and therefore offers great advantages in quality and efficiency for industrial cell line engineering. Partnering with forward-looking leaders in their field, such as Horizon, is a key part of our strategy to provide innovative and quality products to our patients.”

“We are delighted to be working with Hisun on the final development stage for this cell line, the first of several Horizon projects aimed at GMP production of therapeutic proteins,” commented Dr Brian Burke, Business Development Manager at Horizon. “Cell line development has yet to match the gains made in media and feed technology development.  Precision gene editing will be a key driver for cell line development, and by selective partnering with leaders like Hisun, Horizon intends to accelerate this process.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon, Abcam Sign License and Supply Agreement
Horizon Discovery Group plc and Abcam plc have announced the formation of a license and supply agreement between the two companies.
Wednesday, September 09, 2015
Scientific News
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos